Castle Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

• Castle Biosciences Inc CSTL.OQ reported quarterly adjusted earnings of 33 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of nine analysts for the quarter was for earnings of 5 cents per share. Wall Street expected results to range from -12 cents to 16 cents per share.

• Revenue rose 30.5% to $86.31 million from a year ago; analysts expected $81.91 million.

• Castle Biosciences Inc's reported EPS for the quarter was 32 cents​.

• The company reported quarterly net income of $9.59 million.

• Castle Biosciences Inc shares had fallen by 5.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 229.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "strong buy"

Wall Street's median 12-month price target for Castle Biosciences Inc is $40.00

This summary was machine generated from LSEG data February 28 at 11:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)